Defined Sleep to Share Groundbreaking Research at the American Psychiatric Association 2024 Conference
Defined Sleep to Share Groundbreaking Research at the American Psychiatric Association 2024 Conference
Exhibition booth will provide research, clinical trial results, and supplement samples to conference attendees
Defined Sleep, a pioneer in scientifically developed, supported, and validated CBD sleep supplements, is proud to announce its upcoming participation in the American Psychiatric Association (APA) 2024 Annual Meeting from May 4-8, 2024. This key event, held in New York City, gathers mental health professionals from around the world to connect and engage with exhibitors featuring new trends, innovations, and therapeutics in psychiatry.
At the conference, Defined Sleep will showcase its latest research findings at their exhibition booth on the critical link between sleep quality and mental health. The Defined Sleep research team, led by Dr. Paul Muchowski, will highlight evidence-based strategies for enhancing sleep hygiene to improve overall mental well-being.
Key Features of Defined Sleep's Participation in This Meeting:
- Evidence-based Research: Latest studies demonstrating the impact of sleep management on mental health.
- Expertise in Science: The founder of Defined Sleep will share information about practical sleep hygiene techniques for mental health professionals.
- Networking Opportunities: Discussions on how mental health practitioners can integrate these insights into their clinical practice.
"We are excited to bring our cutting-edge research to the forefront at the APA 2024 conference," says Dr. Paul Muchowski, Founder and Lead researcher at Defined Sleep. "Our commitment is to bridge the gap between sleep science and mental health care, providing actionable solutions that practitioners can apply in their work."
Defined Sleep’s involvement in the APA conference underscores its dedication to fostering deeper understanding and innovation in mental health care through improved sleep science.
For additional details about Defined Sleep’s role at the APA 2024 conference or to arrange an interview with Dr. Muchowski, please visit https://definedsleep.com/pages/contact-us.
About Defined Sleep
Defined Sleep is the first CBD sleep supplement using a rational drug design that includes eight terpenes, which act as amplifiers for CBD. After years of scientific research, Dr. Paul Muchowski, renowned neuroscientist with a Ph.D. from the University of Washington and further training with Dr. Ulrich Hartl at the Max Planck Institute for Biochemistry, developed Defined Sleep to further his mission to develop proprietary, clinically proven CBD-based products targeted at the relief of major human ailments. Defined Sleep is the only research-based CBD supplement backed by a clinical trial on the market.
Alexis Quintal
grow@rosarium.work
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507298071/en/
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now